CCL2 and infection: The increased release of TNF-α, IL-23, CCL2, CXCL8, and CXCL10 by sc1o-treated MdMs may contribute to a pro-inflammatory environment at the infection site and thereby promote the immune response against pathogens via several mechanisms.